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Abstract 
 Background: The Bretschneider HTK solution is used widely for 
multiorgan preservation for transplantation, as well as a cardioplegic agent 
that allows single dose administration which is an attractive option for 
lengthy complex cardiac surgery. It was proved that it is simple to use, safe 
and practical. Moreover, it is considered to confer sufficient myocardial 
protection for more than 2 h of cardiac arrest. We undertook this descriptive 
study to analyze the performance of HTK solution in patients undergoing 
complex cardiac surgery with mild to moderate impairment of left 
ventricular systolic function. Patients and methods: A total of 50 patients 
underwent different complex cardiac surgery at national heart institute from 
January 2015 to November 2016 using single dose Custodiol cardioplegia as 
the primary and sole cardioplegic agent, their data was prospectively 
collected and their hospital outcome was analyzed as regards to ten study 
endpoints namely Prolonged ventilation, return to theatre for bleeding, renal 
failure, stroke, 30 days mortality, postoperative MI, need for inotropes, time 
on inotropes, ICU stay and hospital stay.  Pre- and postoperative 
echocardiography was done to compare and evaluate the change of LV 
function using the parameters of End Systolic Dimension, End Diastolic 
Dimension, Fraction Shortening and Ejection Fraction of the left ventricle. 
Results: Half of the patients were males. Their age ranged between 16 – 65 
years with a mean (standard deviation) of 47.46(11.10). preoperative ejection 
fraction ranged from 30 % to 49% with a mean (standard deviation) of 41.8 
(6.32), the majority of them (64%) had NYHA class of 3 and half of them 
had CCS of 3. all patients were done electively. The most common 
procedure done was redo DVR 24% (12 patients) followed by Bentall 
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operation 22%(11 patients). This is followed by CABG + MVR 7 patients 
(14%), then an equal number of 6 patients (12%) who underwent redo MVR 
post-infective endocarditis and CABG+ MVrep. The repair of tricuspid valve 
was done for 14 patients (28%) either with MVR or DVR. 4 patients (8%) 
had CABG +AVR for their combined lesions and another equal number of 
two patients (4%) underwent redo CABG and AVR + conduit (valve 
separate tube graft operation). prolonged ventilation occurred in 20% of the 
cases. An equal percentage of 6% of the patients had to return to the 
operative room and had postoperative MI. Renal failure occurred in 4% of 
the patients and as far as 30-day mortality is concerned, a similar 4% of 
patients died within this period. EF and FS were very similar when compared 
together (41.8 ± 6.32 %, 20.8 ± 2.35 % preoperatively compared to 41.92 ± 
7.49%, 20.85 ± 3.25% postoperatively). P value was insignificant (0.937 and 
0.929) respectively. Conclusion: A single dose of an HTK cardioplegic 
solution provides good myocardial protection in complex cardiac surgery 
with mild to moderate impairment of LV function and has a good immediate 
postoperative outcome. 
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Introduction 
 The best method for preserving cardiac muscle viability during 
cardiac surgery without harm to myocardial function deserves extensive 
work and research (Mehlhorn U, 1995). The Bretschneider HTK solution is 
used widely for multiorgan preservation for transplantation, as well as a 
cardioplegic agent that allows single dose administration (Arslan A, 2005). It 
was proved that Custodiol HTK solution is simple to use, safe and practical 
and administered as one single dose. Moreover, it is considered to confer 
sufficient myocardial protection for more than 2 hours of cardiac arrest 
(Gamal Z., 2014). 
Custodiol is definitely attractive for cardiac surgeons as it is delivered 
as a single dose and can offer myocardial protection for up to three hours 
(Bretschneider HJ., 1980, Gebhard MM, 1984) hence facilitating a proper 
technical flow of complex surgical procedures without interruption. 
Examining the clinical performance of this particular solution in complex 
heart surgery and LV impairment had received a little attention. We therefore 
undertook this descriptive study to investigate this aspect. 
 
Study endpoints 
 Our primary study endpoints were ten points of early postoperative 
events. Prolonged ventilation, return to theatre for bleeding, renal failure, 
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stroke, 30-day mortality, postoperative MI, postoperative intra-aortic balloon 
pump (IABP) insertion and /or need for inotropes, time on inotropes, ICU 
stay and hospital stay. 
 MI was defined as at least two of the following: (1) CKMB of 100 
µg/L or more and/or troponin  I of 3.0 µg/L or more, (2) appearance of new 
postoperative Q waves on the EKG of more than 0.03 seconds, and (3) a new 
hypokinetic or akinetic area in the left or right ventricle by 
echocardiography. New renal failure was defined as at least two of the 
following: serum creatinine increased to > 0.2 mmol/l, doubling or greater 
increase in serum creatinine over the preoperative value and a new 
requirement for renal replacement therapy. Stroke was defined as any new 
permanent neurological deficit lasting more than 72 hours after cardiac 
surgery and was confirmed by computed tomography whenever possible. 
Prolonged ventilation is defined as more than 24hours ventilation. Low 
cardiac output syndrome was defined as the need for postoperative 
intraaortic balloon pump or inotropic support for longer than 30 minutes in 
the intensive care unit to maintain the systolic blood pressure greater than 90 
mm Hg. 
  
Surgical technique 
 Hemodynamic monitoring was carried out via an arterial line in the 
radial and/or femoral artery as well as urine output via a urinary catheter. 
Conventional general anesthesia was used in all patients. The surgical 
approach was via median sternotomy. 
 After aortic cross-clamping, the cardioplegic arrest was induced by 
giving patients 20 ml/kg of HTK cardioplegic solution (Custodiol; Koehler 
Chemi, Alsbach-Hδhnlein, Germany) once. Each liter contained 15 mmol/l 
sodium chloride,10 mmol/l potassium chloride, 18 mmol/l histidine 
hydrochloride, 180 mmol/l histidine, 4 mmol/l magnesium chloride, 2 
mmol/l tryptophan, 30 mmol/l mannitol, 0.015 mmol/l calcium chloride, and 
1 mmol/l potassium hydrogen 2-ketoglutarate (osmolarity 310 /kg, pH 7.02-
7.20). The cardioplegic solution was administered at a temperature of 4-8°C 
in an antegrade fashion at an initial perfusion pressure of 80–100 mmHg. 
When the myocardium was at standstill, the perfusion pressure was 
maintained at 40–60 mmHg. the systemic temperature was lowered to 32°C. 
 
Patients and methods 
 A total of 50 patients underwent different complex cardiac surgery at 
national heart institute from January 2015 to November 2016 using single-
dose Custodiol cardioplegia as the primary and sole cardioplegic agent, their 
data was prospectively collected and their hospital outcome was analyzed as 
regards to ten study endpoints namely Prolonged ventilation, return to theatre 
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for bleeding, renal failure, stroke, 30 days mortality, postoperative MI, need 
for inotropes, time on inotropes, ICU stay and hospital stay. Pre- and 
postoperative echocardiography was done to compare and evaluate the 
change of LV function using the parameters of End Systolic Dimension in 
cm, End Diastolic Dimension in cm, Fraction Shortening in percentage and 
Ejection Fraction of the left ventricle in percentage. 
 Table 1. demonstrates the preoperative and clinical criteria of the 
study group. Half of them males. Their age ranged between 16 – 65 years 
with a mean (standard deviation) of 47.46 (11.10). The incidence of DM and 
hypertension was similar in the study group (56%) and the minority was 
smokers (20%)and having COPD (10%). preoperative ejection fraction 
ranged from 30 % to 49% with a mean (standard deviation) of 41.8 (6.32), 
19 patients (38%) had preoperative pulmonary hypertension. 15 patients 
(30%) experienced MI before their operation and as far as their clinical status 
was concerned, the majority of them (64%) had NYHA class of 3 and half of 
them had CCS of 3. all patients were done electively. 
 Table 2 shows the operative details of the study group. The most 
common procedure done was Redo DVR 24% (12 patients) followed by 
Bentall operation 22% (11 patients). This is followed by CABG + MVR 7 
patients (14%), then an equal number of 6 patients (12%) who underwent 
redo MVR post-infective endocarditis and CABG+ MVrep. The repair of 
tricuspid valve was done for 14 patients (28%) either with MVR or DVR. 4 
patients (8%) had CABG +AVR for their combined lesions and another 
equal number of two patients (4%) underwent redo CABG and AVR + 
conduit (valve separate tube graft operation). Cardiopulmonary bypass time 
ranged from 100 – 184 minutes with a mean (standard deviation) of 149.10 
(33.43). Cross-clamp time ranged between 65 – 140 minutes with a mean 
(standard deviation) of 111.30(28.34) minutes and finally, operative time 
ranged between 195 – 315 minutes with a mean (standard deviation) of 
242.50 (43.81). 
Table 1. Demographic criteria of the study group 
Sex 
Females 25 (50.0%) 
Males 25 (50.0%) 
Age (years) 
Mean ± SD 47.46 ± 11.10 
Range 16 – 65 
Smoking 
No 40 (80.0%) 
Yes 10 (20.0%) 
DM 
No 28 (56.0%) 
Yes 22 (44.0%) 
HTN No 28 (56.0%) 
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Yes 22 (44.0%) 
COPD 
No 45 (90.0%) 
Yes 5 (10.0%) 
Dyslipidemia 
No 28 (56.0%) 
Yes 22 (44.0%) 
MI 
No 35 (70.0%) 
Yes 15 (30.0%) 
LVEF (%) 
Mean ± SD 41.8 ± 6.32 
Range 30 – 49 
Pul. HTN (mmHg) 
No 31 (62.0%) 
Yes 19 (38.0%) 
NYHA 
1 2 (4.0%) 
2 9 (18.0%) 
3 32 (64.0%) 
4 7 (14.0%) 
CCS 
1 11 (22.0%) 
2 10 (20.0%) 
3 25 (50.0%) 
4 4 (8.0%) 
DM, Diabetes mellitus; HTN, hypertension; COPD, Chronic obstructive pulmonary disease; 
MI, Myocardial infarction; LVEF, left ventricular Ejection fraction; Pul. HT, Pulmonary 
hypertension; NYHA, New York Heart Functional Association; CCS, Canadian chest pain 
score 
 
Table 2. Operative data of the study group 
 Variable. 
 
Number of patients Percentage 
Tricuspid repair 14 28.00% 
Redo DVR 12 24.00% 
Bentall 11 22.00% 
CABG+MVR 7 14.00% 
Redo MVR(ENDOCARDITIS) 6 12.00% 
CABG + MVrep  6 12.00% 
CABG + AVR 4 8.00% 
Redo CABG 2 4.00% 
AVR + supra CC 2 4.00% 
 Range Mean ± SD 
CPBT (min) 100 – 184 149.10 ± 33.43 
X clamp (min) 65 – 140 111.30 ± 28.34 
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Operative time (min) 195 – 315 242.50 ± 43.81 
DVR, Double valve replacement; CABG, Coronary artery bypass grafting; MVR, mitral 
valve replacement; MVrep, mitral valve repair; AVR, Aortic valve replacement; supra CC, 
supra coronary conduit; CPBT, cardiopulmonary bypass time; X clamp: Cross clamp time.  
  
 Table 3. demonstrates early postoperative outcome, prolonged 
ventilation occurred in 20%of the cases. An equal percentage of 6% of the 
patients had to return to the operative room and had postoperative MI. Renal 
failure occurred in 4% of the patients and as far as 30-day mortality is 
concerned, a similar 4% of patients died within this period. One case had a 
Bentall procedure and experienced excessive postoperative medical bleeding 
returned to theatre for re-exploration. Postoperative consumption 
coagulopathy was diagnosed and in spite of giving the products required, yet 
the patient did not survive. The second mortality was due to postoperative 
MI and cardiogenic shock in a case of redo CABG. Only 2% of patients had 
a postoperative stroke. 84% of patients needed inotropes namely 
(noradrenaline 52%, adrenaline 44%, levosimendan 30%, 24% and balloon 
12%). These inotropes lasted from 12 – 60 hours with a mean (standard 
deviation) of 22.69 (13.3). their stay in the ICU ranged from 48-96 hours 
with a mean (standard deviation) of 73.2 (15.12). Their hospital stay ranged 
from 8 – 12 days with a mean (standard deviation) of 10.3 (1.21). 
Table 3. Early postoperative outcome 
 Early postoperative outcome  Number of patients Percentage 
Prolonged ventilation 10 20.0% 
Return to operative room 3 6.0% 
30-day mortality 2 4.0% 
Stroke 1 2.0% 
Renal failure 2 4.0% 
Post op MI 3 6.0% 
Need for Inotropes  42 84% 
Adrenaline 22 44.0% 
Dobutrex 12 24.0% 
Noradrenaline 26 52.0% 
IABP 6 12.0% 
Levosemindan 15 30.0% 
ICU stay (hours) 
Mean ± SD 
Range 
73.2 ± 15.12 
48 - 96 
Hospital stay (days) 
Mean ± SD 
Range 
10.3 ± 1.21 
8 - 12 
Duration of inotropic support (hours) 
Mean ± SD 
Range 
22.69 ± 13.3 
12 - 60 
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Postop MI, Postoperative myocardial infarction; IABP, intraaortic 
balloon counter pulsation  
 Finally, table 4. depicts the change in LV dimensions and function 
after the operation. No statistical significance was encountered when the 
preoperative and postoperative (predischarge) echocardiography was 
compared together. ESD and EDD decreased slightly from 3.6±0.62 cm, 
5.75±0.59 cm preoperatively to 3.51±0.61 cm, 5.63±0.69 cm postoperatively 
with a p-value of 0.466 and 0.352 respectively. Similarly, EF and FS were 
very similar when compared together (41.8 ± 6.32 %, 20.8 ± 2.35 % 
preoperatively compared to 41.92 ± 7.49%, 20.85 ± 3.25% postoperatively). 
Again, a p-value was insignificant (0.937 and 0.929) respectively. 
Table 4. comparison between left ventricular function pre- and postoperative 
 Preoperative Pre-discharge Paired t-test p-value 
LVEF (%) 41.8 ± 6.32 41.92 ± 7.49 0.079 0.937 
LVESD(cm) 3.6±0.62 3.51±0.61 0.732 0.466 
LVEDD(cm) 5.75±0.59 5.63±0.69 0.935 0.352 
LVFS (%) 20.8 ± 2.35 20.85 ± 3.25 0.088 0.929 
LVEF, left ventricular ejection fraction; LVESD, left ventricular end systolic dimension; 
LVEDD, left ventricular end diastolic dimension, LVFS:  left ventricular fraction 
shortening. 
 
Statistical analysis 
 Data were collected, revised, coded and entered to the Statistical 
Package for Social Science (IBM SPSS) version 20. The qualitative data 
were presented as number and percentages while quantitative data were 
presented as mean, standard deviations and ranges when their distribution 
found parametric by Kolmogorov-Smirnov tests. The comparison between 
two paired groups with quantitative data and parametric distribution was 
done by using the Paired t-test. The confidence interval was set to 95% and 
the margin of error accepted was set to 5%. So, the p-value was considered 
significant at the p-value < 0.05. 
 
Discussion 
 There is currently a growing interest in the use of variable 
cardioplegic solutions for heart operations. Consequently, a number of 
different solutions and various methods had developed (Mitsuhiro Hachida, 
1997) each cardioplegic method has its own advantages and disadvantages. 
All of them should be used appropriately by taking into account the 
characteristics of myocardial injury and the duration of ischemic time.  
 Surgeons, therefore, have learned to tailor their cardioplegic 
techniques to the individual patient and select the most appropriate approach 
to improve their results and decrease complications (Richard D., 2012). 
 Custidiol is an intracellular cardioplegic solution which contains low 
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sodium concentration to arrest the heart in diastole by inhibiting the rapid 
phase of the action potential, this solution contains histidine as a buffer, 
ketoglutarate to improve ATP energy production during reperfusion, 
tryptophan to stabilize the cell membrane, and mannitol to decrease cellular 
edema and to act as a free radical scavenger(Gamal Z., 2014). 
 The well-integrated components of this solution contribute to 
myocardial preservation and recovery of its function. Aarsaether et al. 
(Aarsæther, 2009) proved that protein buffers such as histidine might be 
superior to bicarbonate in stabilizing intracellular pH and consequently, the 
recovery of postischemic biochemical and mechanical parameters. The 
buffering effect of histidine may be beneficial for severely injured 
myocardium in the dilated heart during prolonged ischemia.  
 The way Histidine improves myocardial preservation was suggested 
by Bretschneider and associates (Bretschneider HJ, 1980). Similarly, Del 
Nido and associates (Del Nido PJ, 1985) proved that histidine had a 
significant cardiac protective effect. The HTK solution contains no metabolic 
substrate nevertheless, it uses a high-capacity buffer system which is 
(histidine). The acidosis is, therefore, efficiently retarded by HTK solutions 
which in turn delay any increase in the cytosolic calcium ion integrity of the 
sarcolemmal membrane (Schmiedl A, 1990). The sarcolemmal ion pumps 
similarly have a low activity by low magnesium ion concentration in the 
HTK solution, thus, further conserving energy reserves. Lastly, because of 
the hypokalemic nature of the HTK solution and its low overall ion 
concentration, provision is made for a significantly higher buffer 
concentration. 
 Takeuchi et al. and Liu et al., in their studies, proved that the 
administration of a histidine-containing cardioplegia solution promotes 
anaerobic glycolysis and improves the recovery of high-energy phosphates 
and contractile function in the hypertrophied myocardium, which supports 
our clinical findings. Owing to these qualities and the high buffer capacity, it 
has been shown that one single dose of HTK is sufficient for myocardial 
protection up to more than 2 hours of ischemia (Takeuchi, 1995, Liu J, 
2008). 
 Other amino acids, such as ketoglutarate and tryptophan, were used 
in HTK to provide an energy source. These components produce adenosine 
triphosphate via the alternative pathway without producing lactate in the 
cells. Moreover, the presence of a high histidine concentration outside the 
cells may also be beneficial because it facilitates Hydrogen ion removal from 
the cytosol by anionic carriers such as lactate during the ischemia (Ohkado 
A, 1994). 
 All these contribute to the significant protective effects of HTK 
solution for prolonged ischemia in the severely injured myocardium. Our 
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study demonstrated that percent fractional shortening and ejection fraction 
after the ischemia did not deteriorate. In conclusion, the results of the present 
study suggest that the protective effect of the HTK method may be 
significant in patients with impaired heart function and undergoing complex 
cardiac surgery. 
 Del Nido et al. (Del Nido PJ, 1985) also demonstrated that 
myocardial necrosis can be minimized and the post-arrest contractile 
function can be better by buffering capacity in a crystalloid solution via 
preserving myocardial adenosine triphosphate stores. 
 Similarly, Hachida et al. (Hachida M, 1997) demonstrated that the 
promotion of anaerobic glycolysis during ischemia by HTK solution results 
in superior preservation of the contractile function of the heart. 
 Saitoh et al (Saitoh Y., 2000) proved that the preservation of HTK 
solution doesn't only protects the myocardium but also the coronary artery 
endothelium. In his experimental study with rat hearts, he found that HTK 
protected the coronary vasculature which can lead to improved functional 
cardiac recovery. 
 Sakata et al. (Sakata J, 1998) used the HTK solution for valve surgery 
and found more spontaneous defibrillation and lower requirement of 
inotropic drugs compared with the use of cold blood cardioplegia. Von 
Oppell et al. (Von Oppell U, 1990) stored cultures of human endothelial cells 
in different cardioplegic solutions and temperatures. According to their 
findings, the best available solution for hypothermic endothelial cell 
preservation is HTK. 
 The superiority of HTK solution at hypothermia appears to be due to 
the low chloride content of intracellular solutions and the additives histidine, 
tryptophan and KH-2-. Moreover, It is well known that HTK should not be 
given in higher temperature in clinical practice as this may result in a stone 
heart (Fabiano F., 2013). 
 Many authors compared HTK solution with blood cardioplegic 
solutions. Braathen et al. (Braathen B, 2011) found that a single dose of HTK 
solution resulted in outcomes similar to those achieved with multidose cold-
blood cardioplegia for mitral valve surgery. However, the same group found 
that HTK did not provide as good protection as cold-blood cardioplegia for 
aortic valve surgery (Braathen B, 2010).  
 In 2006 Braathen et al (Braathen B, 2006) showed that the Custodiol 
group had better left-ventricular contraction preservation, superior 
mitochondrial function, and using myocardial biopsy specimens, 
significantly lower markers of myocardial damage than  cold-blood 
cardioplegia. 
 It was found that postoperative cardiac enzyme release has been 
associated with diminished long-term survival (Domanski MJ, 2011) 
European Scientific Journal October 2017 edition Vol.13, No.30 ISSN: 1857 – 7881 (Print) e - ISSN 1857- 7431 
294 
Similarly, perioperative low cardiac output syndrome has been associated 
with a higher incidence of complications (Rao V, 1996). These two can 
occur with postoperative MI. In this study, we did not measure postoperative 
cardiac enzymes as a routine but only when clinically indicated (like 
suspicion of postoperative MI) as per hospital protocol. 
 In a recent systemic review, offers myocardial protection that is 
equivalent to that of conventional cardioplegia (blood or extracellular 
crystalloid). However, the body of evidence available from which we can 
draw conclusions is limited by the small number of randomised patients. A 
single dose cardioplegia strategy for myocardial protection has significant 
benefits for the performance of minimally invasive or complex cardiac 
surgery and the analysis of this recent review supported its ongoing use. 
However, there was not enough evidence to recommend the routine use of 
for the performance of coronary artery bypass grafting (CABG) or other 
simple open cardiac surgical procedures (James B., 2013). 
 
Conclusion 
 A single dose of an HTK cardioplegic solution provides good 
myocardial protection in complex cardiac surgery with mild to moderate 
impairment of LV function and has a good immediate postoperative 
outcome. 
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